Model-informed precision dosing: State of the art and future perspectives

• Published in: Advanced drug delivery reviews 2024-12, Vol.215, p.115421, Article 115421
• Main Authors: Minichmayr, I.K., Dreesen, E., Centanni, M., Wang, Z., Hoffert, Y., Friberg, L.E., Wicha, S.G.
• Format: Article
• Language: English
• Subjects: Anti-infectives; Immunosuppression; Inflammatory bowel disease; Model-informed precision dosing; Oncology
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2024.115421

[Display omitted] Model-informed precision dosing (MIPD) stands as a significant development in personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves beyond traditional therapeutic drug monitoring (TDM) by integrating mathematical predictions of dosing, and considering patient-specific factors (patient characteristics, drug measurements) as well as different sources of variability. For this purpose, rigorous model qualification is required for the application of MIPD in patients. This review delves into new methods in model selection and validation, also highlighting the role of machine learning in improving MIPD, the utilization of biosensors for real-time monitoring, as well as the potential of models integrating biomarkers for efficacy or toxicity for precision dosing. The clinical evidence of TDM and MIPD is discussed for various medical fields including infection medicine, oncology, transplant medicine, and inflammatory bowel diseases, thereby underscoring the role of pharmacokinetics/pharmacodynamics and specific biomarkers. Further research, particularly randomized clinical trials, is warranted to corroborate the value of MIPD in enhancing patient outcomes and advancing personalized medicine.